Tagged with OP

Czech Republic Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past few years and how Scope has moved to employ a younger generation to capitalize on the industry’s technological shift. Moreover,…

UAE Mazen Dalati, general manager for Alcon in the Middle East, discusses the importance of the Middle East for the largest eye care company in the world, and the main changes in the region’s regulatory landscape after more than 20 years of experience. Moreover, he explains why raising awareness is the…

Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally.   US trading partners should take note. There is no longer a…

Czech Republic Augustin Bernát, general manager for the Czech affiliate of ResMed, a company whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, discusses how their digital solutions are bringing benefits to both the patients and the payers in the country. Following extensive discussions, the…

Opinion Brendan Shaw outlines the long road still to travel to meet the UN Sustainable Development goal of ensuring basic healthcare financing for every citizen in the world by 2030 and the vital role that the private sector must play in attempting to meet this challenge.   The majority of developing…

UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”.   The UK now enters an 11-month transition period to disentangle political and economic ties from a single…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Belgium There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without a reversal of current trends. Against this backdrop, the European Commission is launching the ‘Europe’s Beating Cancer Plan’ to reduce…

Europe An overview of the types of new medicines recommended for approval by the European Medicines Agency (EMA) in 2019. Made with Visme Infographic Maker     A full list of the medicines recommended for approval by the EMA in 2019 Made with Visme Infographic Maker  

China Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to be ground zero for a public health experiment with no recent analogues. The situation—in terms of social and economic dislocation—deteriorates…

Europe Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder collaboration, and the potential impact of a Europe-wide cancer plan.   As health stakeholders, we need to work across the…

Hungary Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials, or radiopharmaceuticals, to examine organ function and structure. Breakthroughs in neurocranial and prostate tumour treatment have brought nuclear medicine into…